Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

Abstract Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex most
commonly associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first …

This statement was developed to promote international consensus on the definition of
borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by …

Background There is paucity of investigations into immunotherapy or targeted therapy for
postoperative locally recurrent pancreatic cancer. We aimed to assess the efficacy of …

Patients with pancreatic cancer commonly develop weight loss and muscle wasting.
Whether adipose tissue and skeletal muscle losses begin before diagnosis and the potential …

Purpose To provide evidence-based recommendations to oncologists and others on
potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO …

Deaths from pancreatic ductal adenocarcinoma, also known as pancreatic cancer, rank
fourth among cancer-related deaths in the United States, yet the causes of pancreatic cancer …

Background Serum carbohydrate antigen (CA 19-9) is the most common tumor marker
assessed in pancreatic cancer patients; nevertheless few articles have comprehensively …

Abstract CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated
Lewis a antigen) is the most commonly used and best validated serum tumor marker for …

CA 19-9 and CEA are the most commonly used biomarkers for diagnosis and management
of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990 …